SCHEMBL3055945

SCHEMBL3055945

CN(C)c1nc(CN(C(=O)C(C)(C)C)c2ccc(F)cc2)cs1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
CASP3 P42574 1/20 0.37
SENP8 Q96LD8 1/20 0.37
SENP7 Q9BQF6 1/20 0.37
SENP6 Q9GZR1 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
RIPK1 Q13546 1/20 0.35
GRM1 Q13255 6/20 0.35
LMNA P02545 1/20 0.34
GRM5 P41594 1/20 0.34
MAPT P10636 2/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3063760 0.92 GRM1 (0.37) MEN1KMT2ANPC1RAB9ACASP3
SCHEMBL3068075 0.91 MAPT (0.35) MEN1KMT2ANPC1RAB9ACASP3
SCHEMBL3065115 0.88 GRIN1 (0.42) NPC1RAB9ACASP3SENP8SENP7
SCHEMBL3058858 0.88 MEN1 (0.44) MEN1KMT2ANPC1RAB9ACASP3
SCHEMBL8173447 0.88 NPC1 (0.42) MEN1KMT2ANPC1RAB9ACASP3
SCHEMBL3059140 0.86 MEN1 (0.45) MEN1KMT2ANPC1RAB9ACASP3
SCHEMBL3068329 0.86 GRIN2A (0.39) GRM1MAPTALDH1A1GAAGRIA2
SCHEMBL3071290 0.85 SMN1; SMN2 (0.38) MEN1KMT2ANPC1RAB9ACASP3
SCHEMBL3059269 0.85 KMT2A (0.42) MEN1KMT2ANPC1RAB9ACASP3
SCHEMBL3064265 0.83 POLB (0.46) MEN1KMT2ASMN1; SMN2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100267697-A1 ION CHANNEL MODULATORS WYETH (US) 2010-10-21 US claimed
EP-2099754-A1 ION CHANNEL MODULATORS Wyeth a Corporation of the State of Delaware (US) 2009-09-16 EP claimed
WO-2008073929-A1 ION CHANNEL MODULATORS WYETH (US) 2008-06-19 WO claimed
US-20100267697-A1 ION CHANNEL MODULATORS WYETH (US) 2010-10-21 US disclosed
US-20100267697-A1 ION CHANNEL MODULATORS WYETH (US) 2010-10-21 US disclosed
US-20100267697-A1 ION CHANNEL MODULATORS WYETH (US) 2010-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267697-A1 ION CHANNEL MODULATORS CACNA1E, CACNA1A, CACNA1S MEN1 2337/4885KMT2A 2712/4885NPC1 481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.